Keyword Search
 
2017 | 2016 | 2015
  • Altimmune Announces its Phase 2 Flu Vaccine Trial with NasoVAX Open for Enrollment
  • September 20, 2017 - 60 Patients to be enrolled Data expected in the first quarter of 2018 GAITHERSBURG, Md., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that they have been cleared by the FDA to initiate their Phase 2 clinical study of NasoVAX, the Company’s intranasally administered recombinant flu vaccine.  NasoVAX is a new type of influenza vaccine that uses intranasal administration to potentially stimulate a broader and more ... 
  • Altimmune to Provide Corporate Update at the Ladenburg Thalmann 3rd Annual Healthcare Conference
  • September 19, 2017 - GAITHERSBURG, Md., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer of Altimmune, will present a corporate overview at the Ladenburg Thalmann 3rd Annual Healthcare Conference, taking place Tuesday, September 26 at the Sofitel Hotel in New York City. Presentation Details Date:        Tuesday, September 26 Time:        12:00pm Eastern Time Location:   Sofite... 
  • Altimmune to Provide Corporate Update at the Rodman & Renshaw Global Investment Conference
  • September 06, 2017 - GAITHERSBURG, Md., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer of Altimmune, will present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference, taking place September 11-12 at the Lotte New York Palace Hotel in New York City. Presentation Details Date: Tuesday, September 12 Time:  1... 
  • Altimmune Closes Series B Preferred Stock Offering
  • August 21, 2017 - GAITHERSBURG, Md., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced it has closed its offering of approximately 15,656 shares of Series B convertible preferred stock and warrants.  The Company received approximately $13.0 million in net proceeds from the offering, after deducting the placement agent fee, an additional fee related to the Company’s completed merger paid to the placement agent, and the Company’s estimated... 
  • Altimmune Submits Investigational New Drug Application for NasoVAX in Preparation for Phase 2 Trial
  • August 21, 2017 - 60 volunteers to be enrolled Data expected in the first quarter of 2018 GAITHERSBURG, Md., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced the Company has submitted an Investigational New Drug (IND) application to the U.S Food and Drug Administration (FDA) for NasoVAX, the Company’s intranasally administered recombinant flu vaccine. NasoVAX uses an adenovector to achieve expression of the influenza antigen in the ... 
  • Altimmune Announces $14.7 Million Series B Preferred Stock Offering
  • August 17, 2017 - GAITHERSBURG, Md., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a definitive securities purchase agreement with new and existing investors to sell an aggregate of 15,656 shares of Series B convertible preferred stock and warrants.  The gross proceeds to the Company are expected to be approximately $14.7 million, before the receipt of proceeds from the exercise of the warrants, if any, and prior ... 
  • Altimmune Announces Second Quarter 2017 Financial Results and Provides Corporate Update
  • August 10, 2017 - Completed merger with PharmAthene, began trading on NASDAQ as Altimmune, Inc. (ALT) Remains on track to initiate Phase 2 trial in NasoVAX in Third Quarter HepTcell Phase 1 clinical trial ongoing in the UK and South Korea, top-line data expected in Fourth Quarter Conference call and webcast at 8:30 a.m. Eastern time GAITHERSBURG, Md., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced financial results for the three... 
  • Altimmune to Announce Second Quarter 2017 Financial Results on August 10
  • July 31, 2017 - GAITHERSBURG, Md., July 31, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will report financial results for the three and six months ended June 30, 2017 before the market open, and host a conference call at 8:30am Eastern Time on Thursday, August 10th, 2017. Conference Call Details   Date:    Thursday, August 10 Time:    8:30am Eastern Time Domestic: ... 
  • Altimmune to Provide Corporate Update at the BIO International Convention
  • June 19, 2017 - Comprehensive, Updated Corporate Presentation Now Available GAITHERSBURG, Md., June 19, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer of Altimmune, will present a corporate overview at the BIO International Convention, taking place June 19-22 at the San Diego Convention Center in San Diego, California. Presentation Details Date: Tuesda... 
  • Altimmune Promotes Dr. Sybil Tasker to Chief Medical Officer
  • May 16, 2017 - GAITHERSBURG, Md., May 16, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced the promotion of Sybil Tasker, M.D., FACP, FIDSA, to the position of Chief Medical Officer.  Dr. Tasker joined the company in April 2016 as Senior Vice President, Clinical Research and Development, with responsibility for overseeing Altimmune’s clinical research and development programs. Bill Enright, President and Chief Executive Officer of Altimmun... 
  • Altimmune, Inc. (Nasdaq: ALT) to Ring The Nasdaq Stock Market Opening Bell
  • May 10, 2017 - ADVISORY, May 10, 2017 (GLOBE NEWSWIRE) -- What: Altimmune, Inc. (Nasdaq:ALT), a clinical stage immunotherapeutic biotechnology company, will visit the Nasdaq MarketSite in Times Square.In honor of the occasion, Bill Enright, Chief Executive Officer, will ring the Opening Bell. Where: Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast StudioWhen: Friday, May 12, 2017 – 9:15 a.m. to 9:30 a.m. ET Altimmune Contact: Matthew Duffy Investor Relations 212-915-0685 m... 
  • Altimmune Completes Merger with PharmAthene Creating Immunotherapeutics Company Targeting Infectious Diseases
  • May 04, 2017 - GAITHERSBURG, Md., May 04, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT) announced today the completion of its merger with PharmAthene, Inc., effective May 4, 2017. Upon the completion of the merger, the combined company was renamed Altimmune, Inc., and will commence trading on The NASDAQ Capital Market under the ticker symbol “ALT” on May 5, 2017. The combined company is a fully integrated and diversified immunotherapeutics company with one preclinical-stage and four clinical-stage dr... 
  • PharmAthene and Altimmune Announce Combined Company Approved for Trading on Nasdaq Global Market
  • April 26, 2017 - ANNAPOLIS, Md. and GAITHERSBURG, Md., April 26, 2017 (GLOBE NEWSWIRE) -- As previously announced, PharmAthene, Inc. (NYSE MKT:PIP) and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, have signed a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Today, the companies announced that, pending approval of the merger between the two companies by PharmAthene's stockholders at a special meeting of PharmAthene's sto... 
  • Altimmune Receives $7.3 Million Contract Modification from BARDA to Fund Manufacturing of its First-In-Class Anthrax Vaccine Candidate NasoShield™
  • March 28, 2017 - ... 
  • Altimmune to Present at The Bio Ceo & Investor Conference
  • February 06, 2017 - ... 
  • Pharmathene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases
  • January 19, 2017 - ... 
  • Altimmune Announces Acceptance of Heptcell Abstract for Presentation at Bsi/Nvvi Congress 2016
  • December 06, 2016 - ... 
  • Altimmune to Present at THR 28th Annual Piper Jaffray Healthcare Conference
  • November 18, 2016 - ... 
  • Altimmune Announces Poster Presentation of Heptcell Program at 2017 Keystone Symposia Conference
  • October 26, 2016 - ... 
  • Altimmune Announces Addition of Christine Brennan to Board Of Directors
  • September 13, 2016 - ... 
  • Altimmune to Present at 18th Annual Rodman & Renshaw Global Investment Conference
  • August 30, 2016 - ... 
  • Altimmune Receives Barda Contract of Up to $120.2 Million to Fund Clinical Development of First-In-Class Anthrax Vaccine Candidate Nasoshield
  • August 01, 2016 - ... 
  • Altimmune to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
  • July 12, 2016 - ... 
  • Altimmune to Participate in Two Upcoming Conferences
  • May 03, 2016 - ... 
  • Altimmune Announces Participation in Vaccine Development Panel at The Annual Regional Biotech Forum
  • April 13, 2016 - ... 
  • Altimmune Expands Clinical Development Team
  • April 05, 2016 - ... 
  • Altimmune to Present at two Upcoming Conferences
  • March 01, 2016 - ... 
  • Altimmune Announces Presentation at BIO CEO & Investor Conference
  • January 26, 2016 - Gaithersburg, Maryland – Jan. 26, 2016 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at the BIO CEO & Investor Conference to be held February 8 - 9, 2016 in New York, NY.Bill Enright, Chief Executive Officer of Altimmune, is scheduled to present on Monday, February 8, 2016 at 8:00 a.m. ET.About Altimmune Altimmune is a clinical stage immunotherapeutic company focused on the development of products to stimulate robust and du... 
  • Altimmune Announces Presentation at Biotech Showcase 2016
  • December 21, 2015 - Gaithersburg, Maryland – DEC. 21, 2015 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at Biotech Showcase 2016 to be held January 11 – 13, 2016 in San Francisco, CA.Bill Enright, Chief Executive Officer of Altimmune, is scheduled to present on Tuesday January 12, 2016 at 4:45 p.m. PST. The presentation will be held in the Hearst room of the Parc 55 Hotel.About Altimmune Altimmune is a clinical stage immunotherapeutic company foc... 
  • Altimmune Chief Scientific Officer to Present at Two Premier Vaccine Conferences
  • October 12, 2015 - Gaithersburg, Maryland – Oct. 12, 2015- Altimmune, Inc., (formerly Vaxin Inc.) a clinical stage immunotherapy and vaccine company, today announced that Chief Scientific Officer M. Scot Roberts, PhD, will present at two premier vaccine conferences in the coming weeks. The first is Bacillus ACT 2015, the international conference on Bacillus anthracis, B. ceres & B. thuringiensis, to be held later this month in New Delhi, India. The second is Vaccines R&D-2015, presented by the United Scien... 
  • Altimmune Ceo to Present at the 2015 Ladenburg Thalmann Healthcare Conference in New York City
  • September 28, 2015 - Gaithersburg, Maryland – Sept 28, 2015- Altimmune Inc., (formerly Vaxin Inc.) a clinical stage immunotherapy and vaccine company, today announced that CEO Bill Enright will present at the 2015 Ladenburg Thalmann Healthcare Conference to be held tomorrow at the Sofitel Hotel in New York City. Enright’s presentation will take place at 11:30am ET.For information on Ladenburg Thalmann, please visit www.ladenburg.com.About Altimmune Altimmune is a clinical stage biotechnology company developing next... 
  • Vaxin Changes Company Name to Altimmune
  • September 01, 2015 - Move Reflects Company’s Expansion beyond Vaccines to Include ImmunotherapeuticsGaithersburg, Maryland – Sept 1st 2015- Vaxin Inc., a clinical stage immunotherapy and vaccine company, today announced that it has changed its corporate name to Altimmune, Inc. Vaxin was founded in 1997 to pioneer new-generation vaccine technologies and products. Since then, the company has achieved steady success, developing promising vaccine candidates for biodefense and other public health needs, as well as animal... 
  • Vaxin First-in-Man Phase I Clinical Trial Initiated in Chronically Infected Hepatitis B Patients
  • July 27, 2015 - Gaithersburg, Maryland – July 27 2015- Vaxin Inc., a clinical stage vaccine and immunotherapeutics company, today announced that it has enrolled the first patient into a phase I clinical trial of HepTcell™ (FP-02.2), the company’s immunotherapeutic compound to treat people chronically infected with the hepatitis B virus (HBV). The multicenter trial will be conducted at seven sites within the United Kingdom, and aims to recruit 72 patients with chronic HBV infection.The trial is a randomized, dou... 
  • Vaxin Strengthens Intellectual Property Portfolio
  • July 21, 2015 - Gaithersburg, Maryland – July 21 2015- Vaxin Inc. today announced that it has added key patents to its expanding Intellectual Property (IP) portfolio. The clinical stage vaccine and immunotherapeutics company confirmed that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two patents that protect important elements of its Densigen platform technology for immunotherapeutic treatment of Hepatitis B virus infection, and its RespirVec non-invasive adenoviral... 
  • Study Demonstrates Superior Performance of Vaxin’s Advav Vaccine for Protection against Aerosolized Anthrax
  • April 29, 2015 - Results Published in Clinical Vaccine Immunology Compares AdVAV FavorablyAgainst Only Currently Licensed AlternativeGaithersburg, MD – April 29, 2015 –Vaxin Inc., a clinical stage vaccine development company, today announced that a recently published study demonstrated that utilizing a single vaccination with the company’s AdVAV™ intranasal anthrax vaccine performs as well as the currently licensed Anthrax Vaccine Absorbed (AVA; BioThrax®), which requires two vaccinations. AdVAV is administered ... 
  • Vaxin Names Elizabeth Adkins Czerepak as Chief Financial Officer
  • April 13, 2015 - Gaithersburg, Md., April 13, 2015 —Today, Vaxin strengthened its leadership team by appointing Elizabeth Adkins Czerepak to the newly created position of chief financial officer (CFO). Vaxin develops vaccines for important public health and biodefense needs. Ms. Czerepak is a finance expert with over 20 years of executive experience in the pharmaceutical, biotech, and venture capital industries. As Vaxin’s CFO, she will grow the company’s finance organization, oversee M&A activities, and dri... 

    © 2017 Altimmune, Inc.   All rights reserved.   Terms of Use